Conduit Pharmaceuticals Inc., a clinical stage life science company, has announced that it will transfer the listing of its common stock to The Nasdaq Capital Market. This decision follows the company's compliance with the necessary requirements for the move. The transfer of Conduit Pharmaceuticals' securities to The Nasdaq Capital Market is set to occur at the start of business on May 23, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conduit Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9456426-en) on May 22, 2025, and is solely responsible for the information contained therein.